Data / Form D filings / Xagenic Inc.
Xagenic Inc.: Form D filing
Xagenic Inc., a biotechnology company in Toronto, Ontario, Canada, filed a Form D with the SEC in 2013. The latest, on December 12, 2013, reports $9.6 million sold of a $21.3 million offering to 6 investors.
Find out what Xagenic Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 55 YORK STREET, SUITE 1600, Toronto, Ontario, Canada, M5J 1
- Phone
- (416) 363-1999
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Ontario, Canada
- Year incorporated
- 2010
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1594154
The full lists. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Form D filings: 44,302 rows, $523.02, or the new rows each week for $92.05 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Dec 12, 2013 | New notice | $21,286,648 | $9,588,224 | $11,698,424 | 6 | Nov 26, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Yuri D. Kuzyk | Executive Officer | |
| Jesse A. Treu, Ph.D. | Director | |
| Jack D. Graham | Executive Officer | |
| Shana Kelley, Ph.D. | Executive Officer, Director | |
| Ihor A. Boszko | Executive Officer | |
| Erik A. Holmlin, Ph.D., M.B.A. | Director | |
| Shermaine A. Tilley, Ph.D., M.B.A. | Director | |
| Bruce A. Cohen | Executive Officer, Director |
Every Form D from the week of Dec 9, 2013 · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Xagenic Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.